CoChat

Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett’s Esophagus

Open access
Chak, Amitabh, Buttar, Navtej S., Foster, Nathan R., Seisler, Drew K., Marcon, Norman E., Schoen, Robert, Cruz-Correa, Marcia R., Falk, Gary W., Sharma, Prateek, Hur, Chin, Katzka, David A., Rodriguez, Luz M., Richmond, Ellen, Sharma, Anamay N., Smyrk, Thomas C., Mandrekar, Sumithra J., Limburg, Paul J. · 2015 · Clinical Gastroenterology and Hepatology
Cited by 48

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background & Aims Obesity is associated with neoplasia, possibly via insulin-mediated cell pathways that affect cell proliferation. Metformin has been proposed to protect against obesity-associated cancers by decreasing serum insulin. We conducted a randomized, double-blind, placebo-controlled, phase 2 study of patients with Barrett's Esophagus (BE) to assess the effect of metformin on phosphorylated S6 kinase (pS6K1) -- a biomarker of insulin pathway activation. Methods Seventy-four subjects with BE (mean age 58.7 years; 58 men [78%0; 52 with BE>2 cm [70%] were recruited through 8 participating organizations of the Cancer Prevention Network. Participants were randomly assigned to groups given metformin daily (increasing to 2000 mg/day by week 4; n=38) or placebo (n=36) for 12 weeks. Biopsy specimens were collected at baseline and at week 12 via esophagogastroduodenoscopy. We calculated and compared percent changes in median levels of pS6K1 between subjects given metformin vs placebo as the primary endpoint. Results The percent change in median level of pS6K1 did not differ significantly between groups (1.4% among subjects given metformin vs – 14.7% among subjects given placebo; 1-sided P=.80). Metformin was associated with an almost significant reduction in serum levels of insulin (median −4.7% among subjects given metformin vs 23.6% increase among those given placebo, P=.08) as well as in homeostatic model assessments of insulin resistance (median −7.2% among subjects given metformin vs 38% increase among those given placebo, P=.06). Metformin had no effects on cell proliferation (based on assays for KI67) or apoptosis (based on levels of caspase 3). Conclusions In a chemoprevention trial of patients with BE, daily administration of metformin for 12 weeks, compared with placebo, did not cause major reductions in esophageal levels of pS6K1. Although metformin reduced serum levels of insulin and insulin resistance, it did not discernibly alter epithelial proliferation or apoptosis in esophageal tissues. These findings do not support metformin as a chemopreventive agent for BE-associated carcinogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2014.08.040

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Chak, A., Buttar, N. S., Foster, N. R., Seisler, D. K., Marcon, N. E., Schoen, R., Cruz-Correa, M. R., Falk, G. W., Sharma, P., Hur, C., Katzka, D. A., Rodriguez, L. M., Richmond, E., Sharma, A. N., Smyrk, T. C., Mandrekar, S. J., & Limburg, P. J.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2015-04
Volume
13
Issue
4
Pages
665-672.e4
ISSN
1542-3565 (ISSN-L)
OpenAlex
W1965316457
Cited by
48
References
6
FWCI
2.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.